|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, HBV infection may contribute to a higher risk for GC based on the meta-analysis and to the morphological atypia of gastric epithelium by the histological assessment, and GC patients among HBV carriers showed lower expression of PD-L1 may lose the chance for immune checkpoint blockade therapy.
|
31471921 |
2020 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that the total number of PD-L1-expressing cells, including tumor and immune cells, is a more sensitive prognostic biomarker than the number of PD-L1-expressing tumor cells in GC.
|
31451991 |
2020 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
|
31463730 |
2020 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated.
|
29727332 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry was performed to detect HLA A/B/C, β2M, CD8, p53, and programmed death-ligand 1 (PD-L1) in the center and invasive margin of the tumor in 395 stage II and III GCs using tissue array method.
|
31620857 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exosomal PD-L1 was an independent prognostic factor in GC (n = 69, 95% confidence interval = 1.142-7.669, P = 0.026).
|
31087180 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, PD-L1 polymorphisms and protein expression were associated with the prognosis of patients with GC.
|
30353572 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that tumor PD-L1 positivity was associated with loss of ARID1A and showed trend toward better survival of patients with various molecular subtypes of GC (experimental set, n = 273).
|
30664822 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of PD-L1 in GC tissues was analyzed immunohistochemically.
|
31372044 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs.
|
30587982 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Aim:</b> PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes were constructed for enhanced therapeutic efficacy against gastric cancer.
|
31290727 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma.
|
31819504 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, PD‑L1 expression was significantly increased in Hp‑positive gastric cancer.
|
31322226 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a new nova of anti-tumor therapy, immunotherapy has been shown to be effective in many tumors of which PD-1/PD-L1 monoclonal antibodies has been proofed to increase overall survival rate in advanced gastric cancer (GC).
|
31722674 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the real effects of fixation conditions on HER-2 testing or PD-L1 testing for gastric cancer using gastrectomy specimens.
|
30842953 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The assessment of human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI) and programmed cell death-ligand 1 (PD-L1) expression is relevant for the selection and effectiveness of targeted therapy in gastric cancer (GC).
|
31595457 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings showed that PD-L1 was overexpressed in GC tissues compared with normal mucosa.
|
30565045 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the prognostic value of ARID1A for gastric cancer and its association with expression of PD-L1 and p53.
|
31043675 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
|
30264329 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380).
|
30729066 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pembrolizumab was approved concurrently with the PD-L1 immunohistochemistry 22C3 pharmDx test (Dako, Agilent, Santa Clara, CA) for selection of patients with gastric cancer for treatment with pembrolizumab based on PD-L1 tumor expression.
|
30120163 |
2019 |
|
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
|
30552042 |
2019 |
|
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the tumor microenvironment of gastric cancer is very complex and the association of PD-L1 with the tumor microenvironment in gastric cancer is still not clear.
|
31519868 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, PD-L1 expression may play a role in immune evasion of gastric cancer.
|
31452748 |
2019 |
|
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of PD-L1 on CD4(+) and CD8(+) cells in GC was higher than in the control group (<i>p</i> < 0.0001).
|
31110545 |
2019 |